PURPOSE: We assessed whether the Gleason grade changes in men followed expectantly with nonpalpable prostate cancer diagnosed on needle biopsy (stage T1c). MATERIALS AND METHODS: We studied 241 men with stage T1c prostate cancer who were treated expectantly with repeat yearly needle biopsy sampling to assess for cancer progression. Following the initial cancer diagnosis all men had at least 1 other biopsy demonstrating cancer. RESULTS: Median patient age was 66 years. The number of biopsies showing cancer over time was 2 in 119 (49.4%), 3 in 74 (30.7%), 4 in 33 (13.7%) and 5 or greater in 15 (6.2%). The average followup for those without progression was 32.3 months. Of 241 cases 45 (18.7%) showed a significant change in grade from Gleason score 6 or less to Gleason score 7 or greater (Gleason score 7 in 41 cases, Gleason score 8 in 4 cases). Of 45 (53.5%) cases 24 that showed progression did so within 24 months of diagnosis. CONCLUSIONS: Within the first 3 years after diagnosis of Gleason score 6 prostate cancer, there is a relatively low risk of grade progression. Within the first 3 years, our data suggest that in most cases tumor grade did not evolve but rather that the higher grade component was not initially sampled since most grade changes occurred relatively soon after biopsy. Grade progression does appear to occur in some men with long-term followup who had multiple biopsies showing Gleason score 6 followed by higher grade cancer.
PURPOSE: We assessed whether the Gleason grade changes in men followed expectantly with nonpalpable prostate cancer diagnosed on needle biopsy (stage T1c). MATERIALS AND METHODS: We studied 241 men with stage T1c prostate cancer who were treated expectantly with repeat yearly needle biopsy sampling to assess for cancer progression. Following the initial cancer diagnosis all men had at least 1 other biopsy demonstrating cancer. RESULTS: Median patient age was 66 years. The number of biopsies showing cancer over time was 2 in 119 (49.4%), 3 in 74 (30.7%), 4 in 33 (13.7%) and 5 or greater in 15 (6.2%). The average followup for those without progression was 32.3 months. Of 241 cases 45 (18.7%) showed a significant change in grade from Gleason score 6 or less to Gleason score 7 or greater (Gleason score 7 in 41 cases, Gleason score 8 in 4 cases). Of 45 (53.5%) cases 24 that showed progression did so within 24 months of diagnosis. CONCLUSIONS: Within the first 3 years after diagnosis of Gleason score 6 prostate cancer, there is a relatively low risk of grade progression. Within the first 3 years, our data suggest that in most cases tumor grade did not evolve but rather that the higher grade component was not initially sampled since most grade changes occurred relatively soon after biopsy. Grade progression does appear to occur in some men with long-term followup who had multiple biopsies showing Gleason score 6 followed by higher grade cancer.
Authors: Spyridon P Basourakos; John W Davis; Brian F Chapin; John F Ward; Curtis A Pettaway; Louis L Pisters; Neema Navai; Mary F Achim; Xuemei Wang; Hsiang-Chun Chen; Seungtaek Choi; Deborah Kuban; Patricia Troncoso; Sam Hanash; Timothy C Thompson; Jeri Kim Journal: BJU Int Date: 2017-08-16 Impact factor: 5.588
Authors: H Ballentine Carter; Alan W Partin; Patrick C Walsh; Bruce J Trock; Robert W Veltri; William G Nelson; Donald S Coffey; Eric A Singer; Jonathan I Epstein Journal: J Clin Oncol Date: 2012-10-01 Impact factor: 44.544
Authors: Ganesh S Palapattu; Simpa S Salami; Andi K Cani; Daniel H Hovelson; Lorena Lazo de la Vega; Kelly R Vandenberg; Jarred V Bratley; Chia-Jen Liu; Lakshmi P Kunju; Jeffery S Montgomery; Todd M Morgan; Shyam Natarajan; Jiaoti Huang; Scott A Tomlins; Leonard S Marks Journal: Clin Cancer Res Date: 2016-10-07 Impact factor: 12.531
Authors: Scott E Eggener; Alex Mueller; Ryan K Berglund; Raj Ayyathurai; Cindy Soloway; Mark S Soloway; Robert Abouassaly; Eric A Klein; Steven J Jones; Chris Zappavigna; Larry Goldenberg; Peter T Scardino; James A Eastham; Bertrand Guillonneau Journal: J Urol Date: 2009-02-23 Impact factor: 7.450
Authors: Jeffrey J Tosoian; Stacy Loeb; Zhaoyong Feng; Sumit Isharwal; Patricia Landis; Debra J Elliot; Robert Veltri; Jonathan I Epstein; Alan W Partin; H Ballentine Carter; Bruce Trock; Lori J Sokoll Journal: J Urol Date: 2012-08-15 Impact factor: 7.450
Authors: Julia H Hayes; Daniel A Ollendorf; Steven D Pearson; Michael J Barry; Philip W Kantoff; Pablo A Lee; Pamela M McMahon Journal: Ann Intern Med Date: 2013-06-18 Impact factor: 25.391
Authors: Paul F Pinsky; Amanda Black; Howard L Parnes; Robert Grubb; E David Crawford; Anthony Miller; Douglas Reding; Gerald Andriole Journal: Cancer Epidemiol Date: 2012-09-19 Impact factor: 2.984